Search the Newsreel

Fate Therapeutics doses first patient in FT819 lupus trial

Fate Therapeutics has dosed the first patient in its Phase 2 RECLAIM-LN clinical trial for FT819, a treatment for refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The trial aims to enroll approximately 53 patients with Class III or IV lupus nephritis, expecting to …

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics has initiated its potentially registrational Phase 2 RECLAIM-LN clinical trial for FT819, an off-the-shelf CAR T-cell therapy, to treat refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. The first patient has been dosed in an outpatient setting, and the study aims …

Fate Therapeutics' First FT819 Patient Went Home Same Day

Fate Therapeutics has initiated its RECLAIM-LN Phase 2 clinical trial for FT819, an off-the-shelf CAR T-cell therapy, in patients with lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, with the study aiming to enroll approximately 53 …

Fate Therapeutics earnings beat by $0.02, revenue topped estimates

Fate Therapeutics (NASDAQ: FATE) announced second-quarter EPS of $-0.250, surpassing analyst estimates by $0.02, and reported revenue of $2.08 million, exceeding the consensus of $1.29 million. The company's stock has seen significant growth, rising 43.590% in the last three months and 131.190% over the …

FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5

Wells Fargo has increased its target price for FATE Therapeutics, Inc. (FATE.O) to $3.5 from $2.5. This update was reported by Reuters on August 14, 2026. The article is a brief financial news alert.

Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Fate Therapeutics (NASDAQ:FATE) reported its quarterly earnings, exceeding analyst expectations with an adjusted loss of $0.25 per share, $0.02 better than estimates, and revenue of $2.08 million against a consensus of $1.37 million. Despite beating expectations, the biopharmaceutical company remains unprofitable, showing a negative …

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics reports Q2 2026: $2.1M revenue, $30.2M net loss, cash $153.8M

Fate Therapeutics announced its Q2 2026 financial results, reporting $2.1 million in revenue and a net loss of $30.2 million. The company ended the quarter with $153.8 million in cash and expects its cash runway to extend into 2028. Additionally, Fate Therapeutics highlighted significant …

Fate Therapeutics: Q2 Earnings Snapshot

Fate Therapeutics (FATE) reported a Q2 GAAP loss of $0.65 per share, which was narrower than the prior year's loss of $0.69 per share. While the company did not generate revenue in the quarter, the results indicate a slight improvement in its financial performance …

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Fate Therapeutics announced its Q2 2026 financial results, highlighting significant clinical milestones including the dosing of the first lupus nephritis patient in its RECLAIM-LN trial for FT819 with same-day discharge. The company also reported FDA clearance for FT839's IND application for an autoimmune disease …

Form 8K Fate Therapeutics Inc For: 13 August By Investing.com

This article from Investing.com reports on the filing of a Form 8K by Fate Therapeutics Inc. for August 13. The brief notice indicates a regulatory filing has been made by the company. It includes no further details about the content of the Form 8K, …

Fate Therapeutics Reports $30.2 Million Second-Quarter Net Loss

Fate Therapeutics (FATE) reported a second-quarter 2026 net loss of $30.2 million on $2.1 million in revenue. The company initiated a Phase 2 trial for lupus nephritis and received FDA clearance for another CAR T-cell product candidate, while its cash reserves declined by $21 …

Fate Therapeutics' First Lupus Nephritis Patient Was Discharged Same Day

Don't Ignore The Insider Selling In Fate Therapeutics

Fate Therapeutics (NASDAQ: FATE) recently saw its President, Bahram Valamehr, sell US$108k worth of stock, representing a 23% reduction in his holdings. This sale, at a price slightly below the current market value, is the largest insider sale in the past year for the …

Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Fate Therapeutics Inc is anticipated to report a loss of 27 cents per share. This information comes from a Reuters earnings preview available on TradingView, which cites Refinitiv as the source for this financial projection.

Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History

This article provides a detailed financial overview of Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company. It includes current stock price, historical data, performance metrics against the S&P 500, and analyst insights. The company specializes in developing programmed cellular immunotherapies for cancer and immune …

Fate Therapeutics (FATE) CEO sells 43,947 shares to cover RSU tax

Fate Therapeutics (FATE) CEO Bahram Valamehr sold 43,947 shares of common stock on August 4, 2026, at a weighted average price of $2.4598 per share. This sale was a mandatory "sell-to-cover" transaction to meet tax withholding obligations arising from the vesting of 75,000 Restricted …

Fate Therapeutics (NASDAQ: FATE) CLO sells 38,800 shares to cover taxes

Fate Therapeutics' Chief Legal and Compliance Officer, Cindy Tahl, sold 38,800 shares of common stock on August 4, 2026, at a weighted average price of $2.4589 per share. This sale was a "sell-to-cover" transaction to meet tax withholding obligations tied to the vesting of …

Fate Therapeutics (FATE) to Release Quarterly Earnings on Tuesday

Fate Therapeutics (NASDAQ:FATE) is scheduled to release its Q2 2026 earnings before the market opens on Tuesday, August 11th. Analysts anticipate a loss of $0.28 per share and revenue of $1.37 million. Despite beating EPS expectations in the previous quarter, the company remains heavily …

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics, Inc. (NASDAQ: FATE) announced new employee inducement awards on August 1, 2026, comprising non-qualified stock options for 37,300 shares to one new non-executive employee and restricted stock units (RSUs) for 45,300 shares to two new non-executive employees. These grants, approved by the …

FATE (FATE) holder discloses 43,947-share potential sale and prior trade

Bahram Valamehr has filed a Form 144 notice indicating a potential sale of 43,947 common shares of FATE Therapeutics Inc. These shares are associated with restricted stock vesting on August 3, 2026, and will be traded on NASDAQ through Fidelity Brokerage Services LLC. The …

Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Fate Therapeutics Inc (FATE), noting its current valuation score of 7.83, which ranks it 188th out of 384 companies in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.17, while also stating …

Fate Therapeutics Inc (FATE) Institutional Confidence

The article analyzes the institutional confidence in Fate Therapeutics Inc (FATE), noting its current institutional shareholding score of 7.00, which ranks 80 out of 385 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 79.47%, representing a quarter-over-quarter decrease of …

FATE|Fate Therapeutics Inc|Price:2.325|Chg%:-0.105

Fate Therapeutics Inc (FATE) is a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies. The stock is currently trading at 2.360 USD, with analysts rating it a "Buy" and a target price of 5.588, suggesting a significant upside. Despite weak short-term performance, the company's …

Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis

Fate Therapeutics Inc (FATE) currently holds a financial score of 5.71, ranking 326 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The company's latest quarterly revenue was $1.30 million, a 20.26% decrease year-over-year, …

Cost of goods sold of Fate Therapeutics, Inc. – HAM:F6T

This article displays a financial page for Fate Therapeutics, Inc. (HAM:F6T) on TradingView, specifically focusing on the company's "Cost of goods sold." The page confirms the market is closed, shows no recent trades, and provides standard navigation for financial data, news, and community features …

Cash flow from operating activities of Fate Therapeutics, Inc. – HAM:F6T

This article focuses on the cash flow from operating activities for Fate Therapeutics, Inc. (HAM:F6T), a biotechnology company listed on the Hamburg Stock Exchange. It appears to be a financial data presentation page from TradingView, indicating no trades and a closed market. The content …

Tangible book value per share of Fate Therapeutics, Inc. – HAM:F6T

This article provides a financial metric, the tangible book value per share, for Fate Therapeutics, Inc. (HAM:F6T). It appears to be a stub or a data point from a financial platform like TradingView, lacking detailed analysis or historical data within the provided content. The …

Operating expenses (excl. COGS) of Fate Therapeutics, Inc. – HAM:F6T

This page from TradingView provides financial information for Fate Therapeutics, Inc. (HAM:F6T), specifically focusing on its operating expenses excluding the cost of goods sold (COGS). It appears to be a financial data portal displaying key metrics for the company.

Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Fate Therapeutics Inc (FATE), outlining major institutional holders and their proportion of shares. It presents data on top shareholders like Redmile Group, LLC, ARK Investment Management LLC, and BlackRock, along with a breakdown of shareholder types and …

Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Fate Therapeutics Inc (FATE) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years and currently shows no dividend data. The page …

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages

Fate Therapeutics (NASDAQ:FATE) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $5.13. Analyst actions have been mixed, and while the company reported a narrower-than-expected quarterly loss of ($0.26) per share, revenue missed estimates. An insider sale …

Fate Therapeutics, Inc. Revenue Breakdown – NASDAQ:FATE

Fate Therapeutics, Inc. (NASDAQ: FATE) generated $6.65 million USD in revenue last year, primarily from its Cellular Immunotherapies segment. This marks a decrease from the $13.63 million USD reported the previous year. The United States was the sole geographic contributor to this revenue.